Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FDEK9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,844
Award facts
- Contract value 100% obligated
- $11,844.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $11,844.15 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml syringes. XOLAIR is a biologic immunosuppressant medication used to treat moderate-to-severe allergic asthma and other allergic conditions. This firm fixed-price delivery order, awarded November 14, 2025, with an ultimate completion date of December 8, 2025, represents a routine pharmaceutical procurement under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency. The award carries no set-aside designation, indicating the company competed without small business or other socioeconomic protections.
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical pharmaceutical supplier to the Department of Defense through its participation in the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The company holds a single-award IDC designated SPE2DR with a $499.999 billion ceiling value extending through December 31, 2036, positioning it as a regional prime vendor contractor within the $30.3 billion PPV-G GEN V acquisition strategy. This delivery order exemplifies DMS Pharmaceutical Group's established role supplying specialized biologics and pharmaceutical products to military healthcare facilities worldwide, with the company demonstrating consistent performance across diverse therapeutic categories and product lines within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FDEK9?
SPE2DR26FDEK9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FDEK9 worth?
The government has obligated $11,844 on SPE2DR26FDEK9.
Is contract SPE2DR26FDEK9 an order under another contract?
Yes. SPE2DR26FDEK9 is a delivery order under SPE2DR25D9112, an indefinite delivery contract.
Was contract SPE2DR26FDEK9 competed?
The extent of competition for SPE2DR26FDEK9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award